Patents Assigned to Resverlogix Corp.
-
Patent number: 11407719Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.Type: GrantFiled: November 18, 2020Date of Patent: August 9, 2022Assignee: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Patent number: 10882828Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.Type: GrantFiled: October 12, 2018Date of Patent: January 5, 2021Assignee: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Patent number: 10772894Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 26, 2018Date of Patent: September 15, 2020Assignee: Resverlogix Corp.Inventors: Ewelina B. Kulikowski, Dean E. Gilham, Sylwia Wasiak, Christopher R. A. Halliday, Henrik C. Hansen
-
Patent number: 10532054Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.Type: GrantFiled: September 20, 2017Date of Patent: January 14, 2020Assignee: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Publication number: 20190119222Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.Type: ApplicationFiled: October 12, 2018Publication date: April 25, 2019Applicant: Resverlogix Corp.Inventor: Henrik C. HANSEN
-
Patent number: 10131640Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.Type: GrantFiled: November 16, 2015Date of Patent: November 20, 2018Assignee: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Patent number: 10111885Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 10, 2016Date of Patent: October 30, 2018Assignee: Resverlogix Corp.Inventors: Ewelina B. Kulikowski, Dean E. Gilham, Sylwia Wasiak, Christopher R. A. Halliday, Laura M. Tsujikawa
-
Patent number: 10016426Abstract: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.Type: GrantFiled: January 18, 2017Date of Patent: July 10, 2018Assignee: Resverlogix Corp.Inventor: Narmada R. Shenoy
-
Patent number: 9757368Abstract: Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.Type: GrantFiled: April 21, 2010Date of Patent: September 12, 2017Assignee: Resverlogix Corp.Inventors: Henrik C. Hansen, Gregory S. Wagner, Sarah C. Attwell, Kevin G. McLure, Ewelina B. Kulikowski
-
Publication number: 20170119767Abstract: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.Type: ApplicationFiled: January 18, 2017Publication date: May 4, 2017Applicant: Resverlogix Corp.Inventor: Narmada R. Shenoy
-
Patent number: 9610251Abstract: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.Type: GrantFiled: October 31, 2012Date of Patent: April 4, 2017Assignee: Resverlogix Corp.Inventor: Narmada R. Shenoy
-
Publication number: 20160346291Abstract: The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through-co-administration of therapeutically effective amounts of a compound of Formula I or a pharmaceutically acceptable salt thereof and rosuvastatin or pravastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin. The invention further provides compositions comprising a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of or pitavastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin.Type: ApplicationFiled: August 21, 2014Publication date: December 1, 2016Applicant: Resverlogix CorpInventor: Kenneth Eugene LEBIODA
-
Publication number: 20160206617Abstract: The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through co-administration of therapeutically effective amounts of RVX-208 or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof. The invention further provides compositions comprising a therapeutically effective amount of RVX-208 or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of rosuvastatin or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 21, 2014Publication date: July 21, 2016Applicant: RESVERLOGIX CORP.Inventors: Kenneth Eugene LEBIODA, Jan Ove JOHANSSON, F. Allen GORDON, Fabrizio Simone CHIACCHIA, Christopher Ross Armstrong HALLIDAY, Ewelina B. KULIKOWSKI
-
Publication number: 20160137613Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.Type: ApplicationFiled: November 16, 2015Publication date: May 19, 2016Applicant: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Publication number: 20160106750Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.Type: ApplicationFiled: October 26, 2015Publication date: April 21, 2016Applicant: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Patent number: 9238640Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.Type: GrantFiled: March 16, 2010Date of Patent: January 19, 2016Assignee: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Patent number: 9199990Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.Type: GrantFiled: October 14, 2014Date of Patent: December 1, 2015Assignee: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Publication number: 20150072955Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.Type: ApplicationFiled: October 14, 2014Publication date: March 12, 2015Applicant: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Patent number: 8952021Abstract: Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds.Type: GrantFiled: January 8, 2010Date of Patent: February 10, 2015Assignee: Resverlogix Corp.Inventor: Henrik C. Hansen
-
Patent number: 8889698Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.Type: GrantFiled: September 23, 2011Date of Patent: November 18, 2014Assignee: Resverlogix Corp.Inventor: Henrik C. Hansen